Melinta Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MELINTA, and what generic alternatives to MELINTA drugs are available?
MELINTA has four approved drugs.
There are sixteen US patents protecting MELINTA drugs.
There are one hundred and thirty-four patent family members on MELINTA drugs in twenty-eight countries and twenty-seven supplementary protection certificates in sixteen countries.
Drugs and US Patents for Melinta
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | 8,420,592 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 8,410,077 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Melinta
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,840,684 | ⤷ Try a Trial |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,998,581 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Melinta Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | 112017000898 | ⤷ Try a Trial |
Japan | 2012501349 | ⤷ Try a Trial |
Russian Federation | 2546667 | ⤷ Try a Trial |
China | 106620649 | ⤷ Try a Trial |
Slovenia | 3056492 | ⤷ Try a Trial |
Cyprus | 1125048 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Melinta Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3214083 | 2021/002 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACIN OR A SALT OR ESTER THEREOF, INCLUDING DELAFLOXACIN MEGLUMINE; NAT REGISTRATION NO/DATE: EU/1/19/1393 20191216; FIRST REGISTRATION NO/DATE: EU/1/19/1393 16/12/2019 (12/10/2022) JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2474) |
2337575 | 2016019 | Norway | ⤷ Try a Trial | PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415 |
3214083 | LUC00196 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACINE OU UN DE SES SELS OU ESTERS, Y COMPRIS LA MEGLUMINE DE DELAFLOXACINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1393 20191219 |
2337575 | 1690041-7 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323 |
3214083 | CA 2021 00002 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACIN ELLER ET SALT ELLER ESTER DERAF, SAERLIGT DELAFLOXACIN MEGLUMIN; REG. NO/DATE: EU/1/19/1393 20191219 |
3214083 | 5/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: DELAFLOXACIN ODER EIN SALZ ODER ESTER DAVON, EINSCHLIESSLICH DELAFLOXACIN-MEGLUMIN; REGISTRATION NO/DATE: EU/1/19/1393 (MITTEILUNG) 20191219 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.